### Summary of Key Events and Insights #### ZaiLab Announces Q1 2025 Financial Report and Conference Call Shanghai and Massachusetts, Cambridge—(Business Wire)—ZaiLab (Nasdaq: ZLAB; HKEX: 9688), a leading international biopharmaceutical company, has announced its plans to release its financial report and provide company updates for the first quarter of 2025 on May 8, 2025, before the U.S. markets open. Following the report, a conference call and webcast will be held at 8:00 AM Eastern Time (8:00 PM Hong Kong Time). Investors and analysts can access the webcast and obtain real-time financial data and company information by visiting ZaiLab's official website at http://ir.zailabor. The report will delve into ZaiLab's performance during the first quarter, highlighting key achievements and outlining future development strategies. This comprehensive update will serve as a crucial reference for market participants. ZaiLab has made significant advancements across various domains in Q1 2025. Notable achievements include breakthroughs in new drug development and the establishment of robust global partnerships. These developments solidify ZaiLab's position as a formidable player in the biopharmaceutical industry, dedicated to enhancing patient outcomes and improving quality of life. ZaiLab's dual listing on Nasdaq and the Hong Kong Stock Exchange enhances its international capital market presence, providing broader access to funding and strategic opportunities. ### Industry Evaluation and Company Profile Industry analysts have praised ZaiLab's consistent performance and strategic initiatives. The company's focus on innovative drug development and global expansion is seen as a key driver of its growth. ZaiLab's robust research and development (R&D) capabilities, coupled with its strong partnerships, position it to address unmet medical needs effectively. The upcoming financial report and conference call are anticipated to provide valuable insights into the company's continued progress and potential future breakthroughs. --- #### Paymentus to Report Q1 2025 Earnings Charlotte, North Carolina—(Business Wire)—Paymentus Holdings, Inc. (NYSE: PAY), a leading provider of cloud-based payment technology solutions, has scheduled its first-quarter earnings report for May 5, 2025, after the market close. The company will also host a webcast and conference call at 5:00 PM Eastern Time on the same day to discuss the financial results in detail. The webcast will offer investors and analysts an in-depth look at Paymentus's business performance and highlights for the quarter. Company executives will share key financial metrics and business updates, and they will be available to answer questions. Those interested in joining the live teleconference can dial +1-833-470-1428 within the United States. Paymentus has established itself as a pioneer in cloud-based payment technology, consistently innovating to enhance consumer payment experiences. The company's solutions are designed to streamline and secure financial transactions, making them more accessible and user-friendly. With a growing customer base and expanding market reach, Paymentus is poised to maintain its leadership in the payment technology sector. ### Industry Evaluation and Company Profile Industry insiders commend Paymentus for its technological advancements and strategic expansions. The company's cloud-based platform is seen as a significant competitive advantage, offering scalability and security in an increasingly digital world. Analysts predict that the Q1 2025 earnings report will likely highlight strong financial performance and continued market growth, reinforcing Paymentus's position as a leader in payment technology. The webcast and conference call are expected to provide detailed insights into the company's operational efficiencies and future business strategies. ### Conclusion Both ZaiLab and Paymentus are set to release their respective Q1 2025 financial reports and host webcasts to provide comprehensive updates on their business performance and strategic developments. ZaiLab's focus on innovative drug development and global expansion, along with its dual listing, highlights its potential for significant growth in the biopharmaceutical industry. Paymentus's technological prowess and market expansion efforts underscore its leadership in the payment technology sector. These events are critical for investors and analysts to gauge the current and future trajectories of both companies.